MARKET

LXEO

LXEO

Lexeo Therapeutics Inc
NASDAQ
2.710
+0.430
+18.86%
After Hours: 2.550 -0.16 -5.90% 17:19 04/17 EDT
OPEN
2.260
PREV CLOSE
2.280
HIGH
2.730
LOW
2.250
VOLUME
608.28K
TURNOVER
--
52 WEEK HIGH
19.50
52 WEEK LOW
1.450
MARKET CAP
89.96M
P/E (TTM)
-0.8760
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LXEO last week (0407-0411)?
Weekly Report · 6d ago
Lexeo Therapeutics: Promising Cardiovascular Gene Therapy Pipeline and Strong Financial Position Justify Buy Rating
TipRanks · 04/10 11:05
Promising Therapeutic Advancements and Strategic Progression Support Buy Rating for Lexeo Therapeutics, Inc.
TipRanks · 04/10 09:16
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 04/09 17:06
Biotech Alert: Searches spiking for these stocks today
TipRanks · 04/09 16:15
Lexeo Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 04/08 11:00
Lexeo Therapeutics Price Target Cut to $22.00/Share From $25.00 by Chardan Capital
Dow Jones · 04/08 11:00
Chardan Capital Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $22
Benzinga · 04/08 10:49
More
About LXEO
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Webull offers Lexeo Therapeutics Inc stock information, including NASDAQ: LXEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXEO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXEO stock methods without spending real money on the virtual paper trading platform.